{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000819","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.940144+00:00","generated_at":"2026-06-15T03:31:37.373552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Charles River Q1 revenue $1.03B, +12.6% YoY; raises organic growth guidance to 5.0-7.5%","bullets":["GAAP EPS $2.01 (+11% YoY); non-GAAP EPS $2.78 (+1.1% YoY); net income $103.1M.","DSA segment revenue $662.4M (+23.6% organic); non-GAAP operating margin 29.0%.","Manufacturing segment revenue $167.3M (-1.8% organic); non-GAAP operating margin 13.7%.","2023 guidance narrowed: organic revenue growth 5.0-7.5% (prior 4.5-7.5%); non-GAAP EPS $9.90-$10.90.","Management cites strong DSA demand but warns Cambodian NHP supply constraints will affect H2."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000819","json":"https://secwatch.observer/filing/0001157523-23-000819.json","markdown":"https://secwatch.observer/filing/0001157523-23-000819.md","text":"https://secwatch.observer/filing/0001157523-23-000819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323000819/0001157523-23-000819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323000819/a53397649.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:31:37.373552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0520b7b8f2eefa6af536ac4713702c3ee655ff81","claim":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the first quarter ended April 1, 2023 results: revenue $1.03 billion, net income $103.1 million, EPS $2.01. Guidance reaffirmed.","evidence_excerpt":"Charles River Laboratories Announces First-Quarter 2023 Results – First-Quarter Revenue of $1.03 Billion – – First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 – – Updates 2023 Guidance –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100682/000115752323000819/0001157523-23-000819-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended April 1, 2023"},{"label":"Revenue","value":"$1.03 billion"},{"label":"Net income","value":"$103.1 million"},{"label":"EPS","value":"$2.01"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}